R-2323

Known as: R 2323, R2323 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1974-1992
024619741992

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
The in vivo effects of gestrinone (R2323) and medroxyprogesterone acetate (MPA) on the estrogen production by rat ovaries were… (More)
Is this relevant?
Review
1991
Review
1991
The progestogens are described by chemical class, and 2 of their uses in gynecology, prevention of miscarriage and treatment of… (More)
Is this relevant?
1988
1988
The effects of P and six synthetic steroids (MPA, ENT, CAP, R2323, DL and EEL) on estradiol dehydrogenase (E2DH) activity were… (More)
Is this relevant?
1986
1986
To understand the mechanism of biological action of gestrinone (R2323), which has a therapeutic effect against endometriosis, the… (More)
Is this relevant?
1982
1982
Twenty patients with endometriosis diagnosed by laparoscopy were treated with the antiestrogen, antiprogesterone gestrinone (R… (More)
Is this relevant?
1981
1981
An in vitro receptor assay system was developed to screen new antiprogestin compounds and to estimate their relative binding… (More)
Is this relevant?
1981
1981
The antifertility mechanism of a new progestin preparation, ethylnorgestrienone (13 beta-ethyl-17 alpha-ethynyl-17-hydroxy-gona-4… (More)
Is this relevant?
1980
1980
The rate of embryo transport through the mouse oviduct was unaltered by ovariectomy after ovulation, essentially unaltered by… (More)
Is this relevant?
1977
1977
6 3 cm polydimethylsiloxane capsules containing 30 mg each of R-2323 were implanted subdermally in each of 38 women to assess… (More)
Is this relevant?